Our recent study demonstrated that sequential Gef treatment added to NP and CPT combination chemotherapy conferred a survival benefit (32.1%, 2-year survival rate) in 28 elderly patients with advanced NSCLC, whose EGFR mutation was unknown (Oshita et al, 2008). This evidence concerns the gene EGFR and non-small cell lung carcinoma.